5 August 2016 - PHARMAC is pleased to announce the approval of an agreement with BGP Products Pty Ltd (trading as Mylan EPD) for the supply of influenza vaccine for the 2017, 2018 and 2019 influenza seasons.

In summary, the effect of this decision is that:

• Influvac will continue to be listed in Section H and Section I of the Pharmaceutical Schedule from 1 January 2017 under the eligibility criteria set by PHARMAC.
• Community Sole Supply Status has been awarded to Mylan EPD for its brands of influenza vaccine from 1 February 2017.
• There will be a change from the trivalent vaccine (Influvac) to the quadrivalent vaccine (Influvac Tetra) from the first full influenza season following Medsafe approval of Influvac Tetra.

Read PHARMAC press release